Oligonucleotide therapeutics - An emerging novel class of compounds;Oligonukleotid therapeutika - Eine neu entstehende substanzklasse

Wiener Medizinische Wochenschrift

Volumn 156, Issue 17-18, 2006, Pages 481-487

  Wacheck, Volker ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antisene; Aptamer; CpG; Oligonucleotide therapeutics; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; FOMIVIRSEN; MESSENGER RNA; PEGAPTANIB; RIBOZYME; SINGLE STRANDED DNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA;

DNA HYBRIDIZATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; REVIEW;

APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

EID: 33750372834     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-006-0331-4     Document Type: Review

References (42)

1. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730
2. Workman P (2004) Drug discovery strategies: technologies to accelerate translation from target to drug. J Chemother 16(Suppl 4): 13-15
3. Pan WH, Clawson GA (2006) Antisense applications for biological control. J Cell Biochem 98: 14-35
4. Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev-Drug Discov 1: 503-514
5. Pirollo KF, Rait A, Sleer LS, Chang EH (2003) Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 99: 55-77
6. Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75: 285-288
7. Patil SD, Rhodes DG, Burgess DJ (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 7: E61-E77
8. Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5: 468-479
9. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644
10. Bayever E, Iversen PL, Bishop MR et al (1993) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 3: 383-390
11. Vitravene Study Group (2002) A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133: 467-474
12. Jason TL, Koropatnick J, Berg RW (2004) Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 201: 66-83
13. Ardizzone S, Bianchi PG (2005) Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286
14. Edmondson SR, Thumiger SP, Werther GA, Wraight CJ (2003) Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr Rev 24: 737-764
15. Wraight CJ, White PJ, McKean SC et al (2000) Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol 18: 521-526
16. Reed JC (2004) Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park) 18: 11-20
17. Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12: 193-213
18. Jansen B, Wacheck V, Heere-Ress E et al (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733
19. Marcucci G, Stock W, Dai G et al (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23: 3404-3411
20. Kirkwood JM, Bedikian AY, Millward MJ et al (2005) Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Proc Am Soc Clin Oncol 24: 7506
21. Koziner B (2004) Potential therapeutic applications of oblimersen in CLL. Oncology (Williston Park) 18: 32-38
22. Tamm I (2006) Antisense therapy in malignant diseases: status quo and quo vadis? Clin Sci (Lond) 110: 427-442
23. Lahn M, Kloeker S, Berry BS (2005) TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 14: 629-643
24. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A et al (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17: 129-139
25. Chi KN, Eisenhauer E, Fazli L et al (2005) A phase I pharmacokinetic and pharmacodynamic study of OCX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296
26. Qiu W, Avramoglu RK, Dube N et al (2004) Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies. Diabetes 53: 3057-3066
27. Olofsson SO, Boren J (2005) Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 258: 395-410
28. Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336-1342
29. Myers KJ, Witchell DR, Graham MJ, Koo S, Butler M, Condon TP (2005) Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 160: 12-24
30. Cech TR, Zaug AJ, Grabowski PJ (1981) In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27: 487-496
31. Khan AU (2006) Ribozyme: A clinical tool. Clin Chim Acta 367: 20-27
32. Rowe PM (1996) Ribozymes enter clinical trials for HIV-1 treatment. Lancet 348: 1302
33. McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3: 737-747
34. Cejka D, Losert D, Wacheck V (2006) Short interfering RNA (siRNA): tool or therapeutic? Clin Sci (Lond) 110: 47-58
35. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178
36. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50-55
37. Ng EW, Shima DT, Calias P, Cunningham ET Jr., Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132
38. Proske D, Blank M, Buhmann R, Resch A (2005) Aptamers-basic research, drug development, and clinical applications. Appl Microbiol Biotechnol 69: 367-374
39. Laber DA, Sharma VR, Bhupalam L, Taft B, Hendler FJ, Barnhart KM (2006) Update on the First Phase I Study of AGRO100 in Advanced Cancer. 2005 ASCO Annual Meeting Abstract, 3064 (Abstract)
40. Klinman DM (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258
41. Hornung V, Rothenfusser S, Britsch S et al (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168: 4531-4537
42. Fedulov A, Silverman E, Xiang Y, Leme A, Kobzik L (2005) Immunostimulatory CpG oligonucleotides abrogate allergic susceptibility in a murine model of maternal asthma transmission. J Immunol 175: 4292-4300